PSYCHEDELIC MEDICINE, HERE AND NOW

A growing network of psychiatry clinics, research sites and therapeutic retreats specialized in psychedelic medicine

Sponsored
Message: The Roundup - Novamind (NM: CSE) (NVMDF: OTC)
 
 

A weekly summary of Novamind news and media

 
 

FEATURES April 23, 2021

Dr. Reid Robison on the Science of Psychedelics

Leafy interviews Novamind’s CMO about how these compounds influence our mind on a molecular level.

FEATURES April 21, 2021

Why Merck Chose Novamind to Lead a Groundbreaking Study

Our CEO and CMO spoke with Streetwise Reports about how Cedar Clinical Research is positioned to develop a new option for treatment-resistant depression.

OPINION April 21, 2021

How Modern Psychedelics Began with a Bike Ride

On April 19, 1943, chemist Albert Hofmann took .00005 teaspoons of LSD. As he rode his bicycle home, he realized that the world had just changed. By Novamind CMO, Dr. Reid Robison and Kirsten Hirst.

 
 
 

Inside Ibogaine, One of the Most Promising and Perilous Psychedelics for Addiction

More Americans died from drug overdoses in 2020 than ever before. As psychedelic-assisted treatment options approach mainstream medicine, Time looks at ibogaine as a way to treat addiction like few treatments can.

 

Psychedelic Drug Worked As Well as Common Antidepressant, Small Trial Finds

Psilocybin works. Researchers in London released findings from a phase 2 trial indicating that a couple of doses of psilocybin may treat depression as well as one of the most commonly prescribed antidepressants. More research is required but leaders of the study were surprised with the outcome.

 
 
 
 
 
 


         Follow @novamind_inc on Instagram


 
Share
New Message
Please login to post a reply